Overexpression of IMP3 is associated with an unfavorable overall survival of patients with epithelial ovarian carcinoma (EOC) [94], such as ovarian clear cell carcinoma (OCCC) [23, 95], ovarian serous carcinoma [96] and primary ovarian mucinous carcinoma [97]. This evidence concerns the gene IMP3 and ovarian serous carcinoma.